Table 2.

Input Parameters: Hepatitis C Model

Model Inputs	Parameters Value	PSA distribution (if applicable)	Source
Cohort characteristics
Age	40		Wright et al.27
Average weight	79.8 kg		Fried et al.28
% male	61		Wright et al.27
Genotype, %
1	66
2 and 3	31		Fried et al.28
4	3
Natural history data
Mild-moderate fibrosis	0.025	Dirichlet	Wright et al.27
Moderate fibrosis-compensated cirrhosis	0.037
Cirrhosis-decompensated cirrhosis	0.04
Cirrhosis-HCC	0.14
Decompensated cirrhosis/HCC-LT	0.02
Decompensated cirrhosis-death	0.13
HCC-death	0.43
LT-Death	0.15
Post-LT-death	0.03
All-cause mortality	Range from 0.014 to 0.335		Interim life table England and Wales, 2008-2010

SVR Rate
	Treatment	Dosage (mg)	Duration (weeks)	SVR Rate (%)	Source
Genotype 1: treatment naïve	Peg-IFN-α-2a	180 (weekly)	48		NICE HTA 25213
	RBV	1,200 (daily)	48	75
	TVR	2,250 (daily	12
Genotype 1: treatment naïve	Peg-IFN-α-2b	120 (weekly)	48		NICE HTA 25312
	RBV	1,000 (daily)	48	66.1
	BOC	2,400 (daily)	32
Genotype 1: patients with cirrhosis (treatment naïve)	Peg-IFN-α-2b	120 (weekly)	48		NICE HTA 25312
	RBV	1,000 (daily)	48	41.7
	BOC	2,400 (daily)	36
Genotypes 2 and 3 (treatment naïve)	Peg-IFN-α-2a	180 (weekly)	24	76	Fried et al.28
	RBV	1,200 (daily)	24
	Peg-IFN-α-2b	120 (weekly)	24	82	Manns et al.29
	RBV	1,000 (daily)	24
Genotype 4 (treatment naïve)	Peg-IFN-α-2a	180 (weekly)	48	77	Fried et al.28
	RBV	1,200 (daily)	48
	Peg-IFN-α-2b	120 (weekly)	48	69	Kamal et al.30
	RBV	1,000 (daily)	48

Health State Costs
	Mean	Standard Error	PSA Distribution		Source
Mild fibrosis	185	36.39			Wright et al.27
Moderate fibrosis	959	101.69	Gamma
Compensated cirrhosis	1,521	309.05
Decompensated cirrhosis	38,871	9410.46			Longworth et al.17
HCC	38,871	9410.46
LT	69,174	7054.86
Post-LT	4,356	861.57

Treatment Costs
	Treatment	Cost			Source
Genotype 1: treatment naïve	Peg-IFN-α-2a and RBV/TVR	32,809			British National Formulary 64 http://www.bnf.org/bnf/index.htm
Genotype 1: treatment naïve	Peg-IFN-α-2b and RBV/BOC	33,270
Genotype 1: patients with cirrhosis	Peg-IFN-α-2b and RBV/BOC	41,670
Genotypes 2 and 3	Peg-IFN-α-2a and RBV	4,446
Genotypes 2 and 3	Peg-IFN-α-2b and RBV	5,435
Genotype 4	Peg-IFN-α-2a and RBV	10,411
Genotype 4	Peg-IFN-α-2b and RBV	10,870

Utilities
	Mean	Standard Error	PSA Distribution		Source
Without treatment with antiviral agents
Mild fibrosis	0.77	0.035	Beta		Wright et al.27
Moderate fibrosis	0.66	0.018
Compensated cirrhosis	0.55	0.032
Decompensated cirrhosis	0.49	0.056			Longworth et al.17
HCC	0.49	0.056
LT	0.51	0.053
Post-LT	0.52	0.061
Death	0	0
During treatment with antiviral agents
Mild fibrosis (during treatment)	0.65	0.035	Beta		Wright et al.27
Moderate fibrosis (during treatment)	0.55	0.018
Compensated cirrhosis (during treatment)	0.44	0.04			Grishchenko et al.31
After successful response to treatment with antiviral agents
Mild fibrosis (SVR after treatment)	0.82	0.04	Beta		Wright et al.27
Moderate fibrosis (SVR after treatment)	0.71	0.05
Compensated cirrhosis (SVR after treatment)	0.60	0.04			Grishchenko et al.31